Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,428 | 805 | 4,572 |
| Samples | 1,649 | 356 | 1,275 |
| Peptides | 1,451 | 247 | 1,216 |
Function
ALMS1 · ALMS1 centrosome and basal body associated protein
This gene encodes a protein containing a large tandem-repeat domain as well as additional low complexity regions. The encoded protein functions in microtubule organization, particularly in the formation and maintanance of cilia. Mutations in this gene cause Alstrom syndrome. There is a pseudogene for this gene located adjacent in the same region of chromosome 2. Alternative splice variants have been described but their full length nature has not been determined. [provided by RefSeq, Apr 2014].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000613296 | Q8TCU4 | 2,018 | 1,436 |
| ENST00000484298 | A0A087WTU9* | 1,792 | 1,350 |
| ENST00000614410 | A0A087WV20* | 1,618 | 1,235 |
Gene Properties
Recurrent Mutations
All 1436 amino-acid changes on canonical ENST00000613296 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ALMS1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ALMS1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 5/25 20% | 0/0 0% |
| Endometrial Carcinoma | 15/42 36% | 55/612 9% |
| Acute Myeloid Leukemia | 9/90 10% | 0/0 0% |
| Melanoma | 28/210 13% | 177/1899 9% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Other Solid Cancers | 13/94 14% | 121/1515 8% |
| Glioblastoma | 8/98 8% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 52/304 17% | 80/1390 6% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 52/810 6% |
| Gastric Carcinoma | 11/74 15% | 98/1809 5% |
| Bladder Carcinoma | 7/58 12% | 49/956 5% |
| Neuroendocrine Tumour | 21/154 14% | 19/577 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 7/133 5% |
| Cervical Carcinoma | 7/35 20% | 17/422 4% |
| Colorectal Carcinoma | 25/143 17% | 142/3239 4% |
| Chondrosarcoma | 2/14 14% | 2/75 3% |
| Small Cell Lung Carcinoma | 4/9 44% | 29/752 4% |
| Rhabdomyosarcoma | 1/33 3% | 7/171 4% |
| Hodgkins Lymphoma | 4/16 25% | 1/122 1% |
| Esophageal Carcinoma | 1/23 4% | 20/769 3% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 59/2550 2% |
| Hepatocellular Carcinoma | 7/46 15% | 51/2210 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Unknown | 1/10 10% | 0/29 0% |
| Ovarian Carcinoma | 13/109 12% | 15/998 2% |
| Biliary Tract Carcinoma | 4/54 7% | 18/950 2% |
| Other Sarcomas | 6/69 9% | 10/699 1% |
| Germ Cell Tumour | 2/25 8% | 2/169 1% |
Mutation Distribution
Where ALMS1 is mutated · all tissues, split by cell line vs tissue
How many mutations in ALMS1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,428 mutations in ALMS1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|